Dear Editor, The Luminex human leukocyte antigen (HLA) single-antigen bead assay (SABA) was developed as a sensitive and specific assay to detect HLA antibodies [1]. However, false positive reactions may occur in the SABA due to the effect of medications such as high-dose intravenous immunoglobulin, anti-thymocyte globulin, and anti-CD20 or the presence of antibodies against denatured HLA [1]. Several approaches to overcome this issue have been proposed, including the use of a pretreatment reagent that adsorbs non-specific antibodies or drugs and acid treatment to distinguish specific antibodies against denatured class I HLA [2]. The use of acid treatment and iBead (singleantigen flow bead) has largely resolved the problem caused by antibodies against denatured class I HLA [2, 3]. However, there is no method for distinguishing antibodies against denatured class II HLA. Antibodies against denatured class II HLA have been detected at a frequency of 11% in healthy male donors [4]. Pan-HLA-DR reactivity is a pattern typically observed in the presence of antibodies against denatured class II HLA [5]. Another study found allelic bead reactions with HLA-DRB1*09:01, DRB3*01:01, DRB3*02:02, DRB3*03:01, DPB1*02:01, DPB1*20:01, and DPB1*28:01 for antibody reaction against denatured class II HLA [6]. Here, we report a case of false positive reaction with an antibody against denatured class II HLA, which showed different reactivities in screening and while using identification beads and SABA kits from different manufacturers. This study was approved by the Institutional Review Board of Severance Hospital, Seoul, Korea (4-2019-0984). A 52-year-old female with end-stage renal disease caused by membranous nephropathy visited Severance hospital for her first kidney transplant in April 2016. She had no history of transfusion or desensitization, such as high-dose intravenous immunoglobulin, anti-thymocyte globulin, or anti-CD20, and her pregnancy history was unknown. The patient did not provide informed consent specific to this study but did provide consent for the test and signed a comprehensive agreement on the potential use of the donated sample for research purposes. Genomic DNA was extracted from the peripheral blood using the QuickGene-Mini80 DNA Isolation System (Fujifilm, Tokyo, Japan). HLA typing was performed without delay using Lifecodes HLA SSO Typing Kits (Immucor Transplant Technology, Stamford, CT, USA), which revealed HLA-A*11, *33; B*27, *54; DRB1*08, *14, DQB1*05, *08. The result of the initial
[1]
Jan U. Becker,et al.
A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology
,
2018,
Transplantation.
[2]
J. Moreau,et al.
Clinical impact of preformed donor‐specific denatured class I HLA antibodies after kidney transplantation
,
2015,
Clinical transplantation.
[3]
C. Jacquelinet,et al.
Denatured Class I Human Leukocyte Antigen Antibodies in Sensitized Kidney Recipients: Prevalence, Relevance, and Impact on Organ Allocation
,
2014,
Transplantation.
[4]
A. Lobashevsky.
Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation.
,
2014,
World journal of transplantation.
[5]
K. Park,et al.
False-Positive Reactions Against HLA Class II Molecules Detected in Luminex Single-Antigen Bead Assays
,
2014,
Annals of laboratory medicine.
[6]
M. Gerbase-DeLima,et al.
Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay.
,
2013,
Human immunology.
[7]
P. Terasaki,et al.
Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood.
,
2009,
Human immunology.
[8]
P. Terasaki,et al.
“Natural” Human Leukocyte Antigen Antibodies Found in Nonalloimmunized Healthy Males
,
2008,
Transplantation.
[9]
P. Terasaki,et al.
HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens.
,
2007,
Human immunology.